- Telix Pharmaceuticals has entered into an agreement to acquire IsoTherapeutics Group, a Texas-based specialty radiopharmaceutical development and bioconjugation firm.
- IsoTherapeutics will continue offering development and manufacturing services to its existing customers and may extend these services to Telix’s strategic partners and collaborators.
Telix Pharmaceuticals, an Australian company, has announced its agreement to acquire IsoTherapeutics Group, LLC, a specialty radiopharmaceutical development and bioconjugation firm based in Angleton, Texas. This strategic move is set to bolster Telix’s in-house drug development capabilities and expand its US manufacturing presence.
IsoTherapeutics, founded in 2005, offers radiochemistry and bioconjugation development, along with contract manufacturing services. It has been serving numerous companies in the radiopharmaceutical industry, including Telix.
“With the agreement to acquire IsoTherapeutics I am pleased to welcome a team of highly recognised industry leaders in bioconjugation and radiochemistry to Telix, as well as further expand our manufacturing footprint in the U.S.,” Christian Behrenbruch, chief executive and managing director of Telix, said in the release.
The acquisition is expected to enhance Telix’s ability to innovate and scale-up manufacturing, especially for clinical trials. It will provide greater control over the isotope supply chain and support the commercialisation of Telix’s investigational therapeutic assets.
Overview of outsourcing trends 
